Roche Holding AG (RHHBY)
| Market Cap | 367.47B +28.8% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 24.06 |
| Forward PE | 17.87 |
| Dividend | 0.97 (1.70%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 319,472 |
| Open | 57.41 |
| Previous Close | 57.14 |
| Day's Range | 57.14 - 57.60 |
| 52-Week Range | 40.07 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 60.30 (+5.53%) |
| Est. Earnings | Oct 21, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $60.3, which is an increase of 5.53% from the latest price.
News
Hansoh Pharmaceutical enters collaboration, license agreement with Roche
Hansoh Pharmaceutical Group (HNSPF) announces that it has entered into a strategic collaboration and license agreement with Roche (RHHBY). This agreement marks the second collaboration between the two...
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
Roche to unveil lung, breast cancer data at ESMO 2026
Roche said on Monday it will present new late-stage trial results at the ESMO 2026 cancer meeting in Madrid, including data showing its lung cancer drug divarasib worked better than current KRA...
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech to present new data at ESMO across oncology portfolio including positive Phase III Krascendo 1 data in lung cancer.
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical...
Genentech announces FDA approval of Enspryng for the treatment of TED
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Enspryng for the treatment of adults with thyroid eye disease, or TED, providing patients with the first and…
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Basel, 16 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab) for the treatment of adults with thyr...
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday.
Roche’s Genentech announces new one-year data from Phase III Meerkat, Sandcat
Genentech, a member of the Roche (RHHBY) Group, announced new one-year data from the Phase III Meerkat and Sandcat studies evaluating investigational vamikibart compared with a sham procedure that mim...
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT s...
Genentech announces FDA approval of Tecentriq combination
Genentech, a member of Roche (RHHBY), announced that the FDA has approved Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III...
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has appro...
FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab an...
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Zealand Pharma said on Wednesday its experimental drug helped people who are overweight or obese and have type 2 diabetes lose up to 9.2% of their body weight in a mid-stage trial. The Danish compan...
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC. Roche will preconfigure the instruments and...
Alector price target raised to $3 from $2 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $3 from $2 and keeps an Underweight rating on the shares after the company announced that Genentech (RHHBY) has…
Why is Alector Stock (ALEC) 60% Higher Today?
Shares in U.S. biotech firm Alector ($ALEC) surged 60% in pre-market trading today after Swiss drugmaker Roche ($RHHBY) agreed to pay up to $1.27 billion. to license its experimental treatment…
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket tra...
Alector enters exclusive AL050 global licensing agreement with Genentech
Alector (ALEC) announced it has entered into an exclusive global licensing agreement with Genentech, a member of Roche (RHHBY), granting Genentech worldwide rights to develop and commercialize Alector...
Roche’s Genentech reports new data from Voyager study of Vabysmo
Genentech, a member of the Roche (RHHBY) Group, announced new data from the Voyager study evaluating the effectiveness, durability and safety of Vabysmo in wet age-related macular degeneration, diabet...
Roche’s Genentech reports detailed results from evERA Breast Cancer study
Genentech, a member of the Roche (RHHBY) Group, announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly im...
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal Conditions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectivene...
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--evERA results published in The New England Journal of Medicine underscore the potential of investigational giredestrant in ER+ advanced breast ...
Roche unit launches LightMix Newborn TREC/SMN1/HBB kit
Roche (RHHBY) announced that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepti...